These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 27965386)

  • 21. Characterization of a high-affinity human antibody with a disulfide bridge in the third complementarity-determining region of the heavy chain.
    Almagro JC; Raghunathan G; Beil E; Janecki DJ; Chen Q; Dinh T; LaCombe A; Connor J; Ware M; Kim PH; Swanson RV; Fransson J
    J Mol Recognit; 2012 Mar; 25(3):125-35. PubMed ID: 22407976
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The trimeric serine protease HtrA1 forms a cage-like inhibition complex with an anti-HtrA1 antibody.
    Ciferri C; Lipari MT; Liang WC; Estevez A; Hang J; Stawicki S; Wu Y; Moran P; Elliott M; Eigenbrot C; Katschke KJ; van Lookeren Campagne M; Kirchhofer D
    Biochem J; 2015 Dec; 472(2):169-81. PubMed ID: 26385991
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Grafting of functional motifs onto protein scaffolds identified by PDB screening--an efficient route to design optimizable protein binders.
    Tlatli R; Nozach H; Collet G; Beau F; Vera L; Stura E; Dive V; Cuniasse P
    FEBS J; 2013 Jan; 280(1):139-59. PubMed ID: 23121732
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of selectivity in homologous multimodal chromatographic systems using in silico designed antibody fragment libraries.
    Karkov HS; Woo J; Krogh BO; Ahmadian H; Cramer SM
    J Chromatogr A; 2015 Dec; 1426():102-9. PubMed ID: 26654254
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery of potent and specific inhibitors targeting the active site of MMP-9 from the engineered SPINK2 library.
    Yano H; Nishimiya D; Kawaguchi Y; Tamura M; Hashimoto R
    PLoS One; 2020; 15(12):e0244656. PubMed ID: 33373399
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biochemical characterization and structure determination of a potent, selective antibody inhibitor of human MMP9.
    Appleby TC; Greenstein AE; Hung M; Liclican A; Velasquez M; Villaseñor AG; Wang R; Wong MH; Liu X; Papalia GA; Schultz BE; Sakowicz R; Smith V; Kwon HJ
    J Biol Chem; 2017 Apr; 292(16):6810-6820. PubMed ID: 28235803
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design and construction of synthetic phage-displayed Fab libraries.
    Bostrom J; Fuh G
    Methods Mol Biol; 2009; 562():17-35. PubMed ID: 19554284
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Exploring the capacity of minimalist protein interfaces: interface energetics and affinity maturation to picomolar KD of a single-domain antibody with a flat paratope.
    Koide A; Tereshko V; Uysal S; Margalef K; Kossiakoff AA; Koide S
    J Mol Biol; 2007 Nov; 373(4):941-53. PubMed ID: 17888451
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Stability and CDR composition biases enrich binder functionality landscapes.
    Hackel BJ; Ackerman ME; Howland SW; Wittrup KD
    J Mol Biol; 2010 Aug; 401(1):84-96. PubMed ID: 20540948
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Generation and optimization of human antagonistic antibodies against TIMP-1 as potential therapeutic agents in fibrotic diseases.
    Brocks B; Kraft S; Zahn S; Noll S; Pan C; Schauer M; Krebs B
    Hum Antibodies; 2006; 15(4):115-24. PubMed ID: 17522433
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comment on "Engineering antibody heavy chain CDR3 to create a phage display Fab library rich in antibodies that bind charged carbohydrates".
    Lucas AH; Reason DC
    J Immunol; 2009 May; 182(9):5160-1. PubMed ID: 19380755
    [No Abstract]   [Full Text] [Related]  

  • 32. The testosterone binding mechanism of an antibody derived from a naïve human scFv library.
    Niemi MH; Takkinen K; Amundsen LK; Söderlund H; Rouvinen J; Höyhtyä M
    J Mol Recognit; 2011; 24(2):209-19. PubMed ID: 21360611
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improving antibody binding affinity and specificity for therapeutic development.
    Bostrom J; Lee CV; Haber L; Fuh G
    Methods Mol Biol; 2009; 525():353-76, xiii. PubMed ID: 19252851
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen.
    Chen Y; Wiesmann C; Fuh G; Li B; Christinger HW; McKay P; de Vos AM; Lowman HB
    J Mol Biol; 1999 Nov; 293(4):865-81. PubMed ID: 10543973
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumor targeting of doxorubicin by anti-MT1-MMP antibody-modified PEG liposomes.
    Hatakeyama H; Akita H; Ishida E; Hashimoto K; Kobayashi H; Aoki T; Yasuda J; Obata K; Kikuchi H; Ishida T; Kiwada H; Harashima H
    Int J Pharm; 2007 Sep; 342(1-2):194-200. PubMed ID: 17583453
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antibody humanization by redesign of complementarity-determining region residues proximate to the acceptor framework.
    Hanf KJ; Arndt JW; Chen LL; Jarpe M; Boriack-Sjodin PA; Li Y; van Vlijmen HW; Pepinsky RB; Simon KJ; Lugovskoy A
    Methods; 2014 Jan; 65(1):68-76. PubMed ID: 23816785
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Converting a broad matrix metalloproteinase family inhibitor into a specific inhibitor of MMP-9 and MMP-14.
    Shirian J; Arkadash V; Cohen I; Sapir T; Radisky ES; Papo N; Shifman JM
    FEBS Lett; 2018 Apr; 592(7):1122-1134. PubMed ID: 29473954
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Selectivity Conversion of Protease Inhibitory Antibodies.
    Lopez T; Ramirez A; Benitez C; Mustafa Z; Pham H; Sanchez R; Ge X
    Antib Ther; 2018 Sep; 1(2):55-63. PubMed ID: 30406213
    [No Abstract]   [Full Text] [Related]  

  • 39. Engineering a high-affinity anti-IL-15 antibody: crystal structure reveals an α-helix in VH CDR3 as key component of paratope.
    Lowe DC; Gerhardt S; Ward A; Hargreaves D; Anderson M; Ferraro F; Pauptit RA; Pattison DV; Buchanan C; Popovic B; Finch DK; Wilkinson T; Sleeman M; Vaughan TJ; Mallinder PR
    J Mol Biol; 2011 Feb; 406(1):160-75. PubMed ID: 21167836
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Arylamino methylene bisphosphonate derivatives as bone seeking matrix metalloproteinase inhibitors.
    Tauro M; Laghezza A; Loiodice F; Agamennone M; Campestre C; Tortorella P
    Bioorg Med Chem; 2013 Nov; 21(21):6456-65. PubMed ID: 24071448
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.